Skip to content
OCUT-2C
Tissue
胸膜
Disease
未分化甲狀腺癌
Metastatic site
胸腔積液
Synonyms
Ocut-2C, OCUT2C, Osaka City University Thyroid-2C

Documents

OCUT-2C

Cell line · Product number 305544

OCUT-2C (Osaka City University Thyroid-2C) is a human anaplastic thyroid carcinoma cell line established from a pleural effusion of an 81-year-old Japanes...

US$700.00excl. tax and shipping
In stock
Lot
Recommended (freshest lot)
  • CoA
1

01General information

Description

OCUT-2C(大阪市立大學甲狀腺-2C)是一種從一名 81 歲日本女性患者的胸腔積液中建立的人類未分化甲狀腺癌細胞系。該細胞系以貼壁單層形式增生。OCUT-2C 攜帶兩種具臨床意義的致癌突變: BRAF p.Val600Glu (V600E) 及 PIK3CA p.His1047Arg (H1047R),這反映了在去分化型及未分化型甲狀腺癌中常見的 MAPK 與 PI3K/Akt 路徑同時活化現象。 同時存在 BRAF V600E 與 PIK3CA H1047R 突變,為研究未分化甲狀腺癌的抗藥性機制及聯合治療策略提供了具臨床相關性的模型。

OCUT-2C 適用於研究未分化甲狀腺癌的生物學特性、BRAF V600E + PI3K H1047R 共突變的生物學機制、MAPK/ERK 及 PI3K/Akt 訊號傳導路徑、標靶治療評估(BRAF 抑制劑、MEK 抑制劑、 PI3K/mTOR 抑制劑),以及聯合治療方案。作為源自日本患者的未分化甲狀腺癌模型,其對於研究此種預後極差、具侵襲性且對治療具抗藥性的惡性腫瘤之生物學特徵具有重要意義。

Tissue
胸膜
Disease
未分化甲狀腺癌
Metastatic site
胸腔積液
Applications
甲狀腺未分化癌研究;BRAF V600E 與 PIK3CA H1047R 共突變的生物學機制;MAPK/PI3K 訊號傳導路徑;BRAF/MEK 抑制劑評估;PI3K/mTOR 抑制劑評估;聯合治療策略;甲狀腺癌藥物抗藥性
Synonyms
  • Ocut-2C
  • OCUT2C
  • Osaka City University Thyroid-2C

02Classification

Organism
Human
Sex
Female
Growth properties
Adherent
GMO status
Non-GMO
GMO status details
No genetic modification; wildtype anaplastic thyroid carcinoma cell line with somatic BRAF V600E and PIK3CA H1047R mutations
Biosafety level
1

03Characteristics

Morphology
上皮樣
Cell type
上皮細胞
Doubling time
約 24 至 48 小時

04Identifiers

Citation
OCUT-2C(Cytion 型號 305544)
NCBI TaxID
9606
Cellosaurus
CVCL_W915

05Expression and susceptibility

Mutational profile
突變:p.Val600Glu,未指定;突變:p.His1047Arg,未指定

06Handling and culture

Culture medium
RPMI 1640,含 2.0 mM 穩定谷氨醯胺,含 2.0 g/L NaHCO₃(Cytion 產品編號 820700a)
Incubation atmosphere

37°C,5% CO₂,加濕環境。

Supplements
在培養基中加入 10% 的胎牛血清(FBS)
Dissociation reagent
Accutase
Subculturing
移除培養基,用不含鈣和鎂的PBS清洗,加入Accutase覆蓋,於室溫下孵育 8–10 分鐘,重新懸浮於培養基中,以 300×g 離心 3 分鐘,棄去上清液,再將細胞接種於新鮮培養基中。
Split ratio
1 至 5
Seeding density
1 至 3 × 10⁴ 個細胞/cm²
Fluid renewal
每 2 至 3 天
Thawing and culturing
  1. Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit.

  2. Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required.

  3. For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains.

  4. Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening.

  5. Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently.

  6. Centrifuge the mixture at 200 x g for 5 minutes, carefully discard the supernatant containing freezing medium.

  7. Follow the procedure described under Post-Thaw Recovery

07Quality control and cryopreservation

Freeze medium
作為冷凍保存培養基,我們使用完全生長培養基加上 10% 的二甲基亞砜(DMSO),以確保解凍後的細胞存活率達到適當水準。
Storage conditions

若需長期保存,請將試管置於溫度約為 −150 至 −196 °C 的氣相液氮中。僅在轉移至液氮之前,可將試管暫時存放於 −80 °C 環境中,作為短期過渡步驟。

Shipping conditions

冷凍保存的細胞系會以乾冰冷藏,並裝於經驗證的隔熱包裝中,包裝內含有足夠的冷媒,以確保在運輸過程中溫度維持在約 −78 °C。收到貨物後,請立即檢查容器,並盡快將試管轉移至適當的儲存場所。

08Donor

Donor age
81Y
Ethnicity
日文